ABCL

AbCellera Biologics Inc. (NASDAQ:ABCL) is a Canadian biotechnology company founded in 2012 and headquartered in Vancouver, Canada. The company went public in December 2020 during the height of the COVID-19 pandemic, largely driven by its successful collaboration with Eli Lilly to develop bebtelovimab, a COVID-19 antibody treatment. AbCellera has since transitioned from primarily being a platform and partnership company to becoming a clinical-stage biotechnology company focused on developing its own pipeline of antibody therapeutics while maintaining selective strategic partnerships.